Medgenics (LON:MEDG) this morning gave an early, but very encouraging hint as to the progress of its potentially revolutionary EPODURE system for treating anaemia in patients on kidney dialysis.
Referring to the first three people enrolled in a phase IIa clinical study, the drugs delivery specialist said “the EPODURE procedure went well”.
The treatment uses the company’s biopump technology, which allows the sustained production of therapeutic proteins.
In the case of the EPODURE system, it provides the platform for erythropoietin, or EPO for short.
The phase IIa study is taking place in Israel and the early information was released in a poster presentation at the American Society of Nephrology’s Kidney week, held in San Diego.
Medgenics said the results thus far were consistent with those seen in the earlier phase I/II study of pre-dialysis patients.
Chief executive Andrew Pearlman said: "We believe that this Phase IIa study will provide valuable insight into the use of EPODURE to treat anaemia in patients on dialysis, which is the largest segment of the anaemia market.
“Although the findings presented at Kidney Week 2012 are on only three patients, we are thus far encouraged by this ongoing study.
“Full study results can be supportive of the larger phase II study in dialysis patients in the US, now slated to begin in the first half of 2013.
“Once completed, we believe these studies will provide data to support the use of EPODURE in the treatment of anaemia from chronic kidney disease."
No comments:
Post a Comment